MedTrace Logo

Examination Of Vitiligo Skin Samples Before and After UVB Treatment

NCT00177034 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2012-07-10

No results posted yet for this study

Summary

The keratinocytes of lesional skin of vitiligo compared to normal and perilesional skin will differentially express genes correlating with melanocyte death. Narrow Band UVB should then hopefully reverse the pattern of gene expression back toward normal.

Conditions

  • Vitiligo

Interventions

DRUG

Narrow Band UVB Treatment

Sponsors & Collaborators

  • American Skin Association

    collaborator OTHER

  • Mimi Cho, MD

    lead INDIV

Principal Investigators

  • Mimi Cho, MD, PhD · University of Minnesota

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00177034 on ClinicalTrials.gov